Health CarePharmaceuticals & Biotechnology
  • Price (GBX)834.50
  • Today's Change0.00 / 0.00%
  • Shares traded275.01k
  • 1 Year change60.48%
  • Beta-0.0005
Data delayed at least 20 minutes, as of Jun 14 2019 16:35 BST.
More ▼

Profile data is unavailable for this security.

About the company

BTG plc is medical device development and healthcare service provider. It provides Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care and licensing business. It operates through three segments: Interventional Medicine, Pharmaceuticals and Licensing. The Interventional Medicine segment includes oncology, vascular and pulmonology. The segment's products include Beads, TheraSphere, EkoSonic, Varithena and PneumRx Coils for use in the treatment of liver tumors, blood clots, varicose veins and advanced emphysema. The Pharmaceuticals segment includes CroFab, DigiFab, Voraxaze and Vistogard products for use in the treatment of crotalid envenomation, digoxin toxicity, high-dose methotrexate toxicity and 5-fluorouracil toxicity. The Licensing segment includes Zytiga, Two-Part Hip Cup and Lemtrada products for use in the treatment of advanced prostate cancer, hip replacement and multiple sclerosis.

  • Revenue in GBP (TTM)690.43m
  • Net income in GBP-18.77m
  • Incorporated1991
  • Employees1.51k
  • Location
    BTG PLC5 Fleet PlaceLONDON EC4M 7RDUnited KingdomGBR
  • Phone+44 207 575 0000
  • Fax+44 207 575 0010
  • Websitehttps://www.btgplc.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
BTG:LSE since
Novate Medical LtdDeal completed07 Sep 201807 Sep 2018Deal completed48.22%150.00m
Data delayed at least 20 minutes, as of Jun 14 2019 16:35 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Advanced Medical Solutions Group plc102.60m22.65m700.70m654.0031.194.0427.196.840.10480.10480.47490.810.56353.034.26156,877.7012.4412.5513.6113.7561.8059.2822.0820.625.64--0.0011.965.8711.5112.5014.7918.1617.08
Clinigen Group PLC422.30m25.30m1.38bn122.0051.543.1424.203.240.20060.20063.333.300.546811.495.043,461,476.003.283.673.815.3436.9934.365.994.991.329.750.361935.9926.1025.47621.0519.31-8.0822.87
Genus plc470.50m-7.10m1.71bn2.79k--3.51104.563.62-0.1153-0.10727.607.470.5964--5.16168,819.50-1.094.71-1.245.36--35.90-1.837.811.69147.000.184241.032.446.37-68.90-15.3021.2110.06
Udg Healthcare PLC1.02bn20.27m1.82bn9.00k90.842.6026.291.790.0810.08174.082.830.848823.743.68117,601.601.683.832.095.1828.9030.091.985.461.8516.400.212453.807.82-13.19-108.24---2.844.99
Hutchison China MediTech Limited168.96m-59.03m2.73bn563.00--9.09--16.52-0.0889-0.08890.25440.46050.378911.955.02300,110.10-12.62-4.33-15.96-6.2732.7731.08-33.29-8.054.19--0.0609---11.2336.03-179.78--20.55--
Dechra Pharmaceuticals plc444.36m25.52m2.91bn1.44k111.735.6827.186.450.24990.2424.364.920.52822.366.09309,230.303.044.143.394.7357.0555.695.757.341.5812.220.385788.0713.3116.56-0.019219.196.6812.74
Abcam Plc245.40m57.90m3.00bn1.10k51.468.0841.6212.110.28080.27941.191.790.62482.698.06223,090.9014.7414.3116.1315.8070.1370.2023.5923.293.13--0.0045.917.4213.8034.5711.7838.9411.26
BTG plc690.43m-18.77m3.25bn1.51k--3.0744.604.70-0.04990.05051.782.730.51953.244.47456,632.10-1.612.71-1.743.0870.5369.02-3.095.976.3110.610.000.0010.6717.37-164.20---1.28--
Hikma Pharmaceuticals Plc1.64bn222.54m4.03bn8.41k17.822.9812.772.420.91960.91966.775.510.6031.983.18194,729.008.280.594311.030.80251.6453.2213.731.021.2811.510.2729518.677.238.75131.615.8713.1313.12
Croda International Plc1.39bn238.30m6.75bn4.58k28.406.8122.914.871.851.8510.757.710.77883.176.36302,816.6013.3814.4315.9717.5937.6635.9817.1816.491.0551.890.332367.
Data as of Jun 14 2019. Currency figures normalised to BTG PLC's reporting currency: UK Pound GBX

Institutional shareholders

41.63%Per cent of shares held by top holders
HolderShares% Held
UBS Asset Management (UK) Ltd.as of 22 Feb 201931.75m8.20%
Pentwater Capital Management LPas of 29 Jan 201930.82m7.95%
Invesco Asset Management Ltd.as of 30 Apr 201930.47m7.86%
Sand Grove Capital Management LLPas of 12 Dec 201816.20m4.18%
The Vanguard Group, Inc.as of 02 May 201911.31m2.92%
Norges Bank Investment Managementas of 13 Mar 20198.88m2.29%
Legal & General Investment Management Ltd.as of 11 Jun 20198.60m2.22%
Standard Life Investments Ltd.as of 03 Jun 20198.34m2.15%
M&G Investment Management Ltd.as of 16 May 20197.62m1.97%
Aviva Investors Global Services Ltd.as of 10 Jun 20197.30m1.88%
More ▼
Data from 31 Dec 2018 - 31 Mar 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.